Bone Biologics Elects New Directors, Adjusts Executive Pay
Ticker: BBLGW · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | 8-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, management-changes
Related Tickers: BBLG
TL;DR
BBLG adds 2 directors, revises CEO/CFO pay packages.
AI Summary
Bone Biologics Corporation announced on March 12, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Steven J. Lee and Mr. David M. Dunshee, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Jagath Reddy, and Chief Financial Officer, Michael J. O'Leary, detailing their compensation and severance packages.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Bone Biologics Corporation (company) — Registrant
- Dr. Steven J. Lee (person) — Newly elected director
- Mr. David M. Dunshee (person) — Newly elected director
- Jagath Reddy (person) — Chief Executive Officer
- Michael J. O'Leary (person) — Chief Financial Officer
FAQ
Who were the newly elected directors to Bone Biologics Corporation's Board of Directors?
Dr. Steven J. Lee and Mr. David M. Dunshee were elected to the Board of Directors.
What is the effective date of the earliest event reported in this 8-K filing?
The earliest event reported is dated March 12, 2024.
What specific items are covered in this Form 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the business address of Bone Biologics Corporation?
The business address is 2 BURLINGTON WOODS DRIVE, SUITE 100, BURLINGTON, MA 01803.
Who are the named executive officers whose compensation arrangements were updated?
The filing mentions new employment agreements for Chief Executive Officer Jagath Reddy and Chief Financial Officer Michael J. O'Leary.
Filing Stats: 823 words · 3 min read · ~3 pages · Grade level 14 · Accepted 2024-03-15 16:45:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BBLG Nasdaq Capital Mark
- $300,000 — . Frelick: (i) an annual base salary of $300,000, (ii) the opportunity to earn an annual
Filing Documents
- form8-k.htm (8-K) — 46KB
- 0001493152-24-010114.txt ( ) — 259KB
- bblg-20240312.xsd (EX-101.SCH) — 4KB
- bblg-20240312_def.xml (EX-101.DEF) — 26KB
- bblg-20240312_lab.xml (EX-101.LAB) — 36KB
- bblg-20240312_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BONE BIOLOGICS CORPORATION Date: March 15, 2024 By: /s/ Jeffrey Frelick Jeffrey Frelick Chief Executive Officer